Global BCG Vaccine market Size by Type, End User and Application: Global Opportunity Analysis
and Industry Forecast, 2020-2025. The base year considered for the study is 2020, and the forecast
has been provided for the period from 2020 to 2025.
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection,
which affects the lungs and sometimes other parts of the body, such as the bones, joints and
kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most
widely used of all current vaccines, reading >80%of neonates and infants in countries where it is
part of the national childhood immunization programme.
The global average gross margin of BCG Vaccine is in an decreasing trend, from 71.59% in 2012 to
69.46% in 2020.With the situation of global economy, gross margin will be in decreasing trend in
the following five years. The type of BCG Vaccine includes Immune BCG and Therapy BCG. The
proportion of Therapy BCG in 2019 is about 92.73%.
BCG Vaccine is widely used in Hospitals and Clinics. The most proportion of BCG Vaccine is sold in
Hospitals and the market share in 2019 is about 74.14%, and the Hospitals have upstream trend.
North America is the largest supplier of BCG Vaccine, with a production market share nearly
32.58% in 2019. Europe is the second largest supplier of BCG Vaccine Media, enjoying production
market share nearly 29.74% in 2019.
North America region is the largest consumption of BCG Vaccine, with a sales revenue market share
nearly 36.40% in 2019. Europe is the second largest consumer of BCG Vaccine, enjoying sales
revenue market share about 32.43% in 2019.
Market competition is not intense. Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec,
Serum Institute of India, Intervax, GSBPL are the leaders of the industry, and they have been formed
in the monopoly position in the industry.
According to this study BCG Vaccine market will register a 5.5% CAGR in terms o